uLab Systems and Biolux Technology Forge Strategic Partnership to Redefine Clear Aligner Therapy

uLab Systems®, a leader in digital orthodontic innovation, and Biolux Technology, creator of the OrthoPulse® near-infrared (NIR) light therapy de...

September 12, 2025 | Friday | News
Zhimeng Biopharma Receives NMPA Approval to Begin Phase 2 Trial of Novel Potassium Channel Opener CB03-154 for Refractory Epilepsy

Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma") announced that its self-developed novel next-generation KCNQ2/3 potassium channel opener, CB03-154...

September 12, 2025 | Friday | News
Scipher Medicine and Maxymune Therapeutics Partner to Advance AI-Driven Target Discovery in Immunology

Scipher Medicine, a pioneer in network-based and AI-driven precision immunology,  announced a strategic collaboration with Maxymune Therapeutics, a ...

September 11, 2025 | Thursday | News
Trethera Completes Enrollment in Phase 1 Trial of TRE-515 for Advanced Solid Tumors

Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune d...

September 11, 2025 | Thursday | News
Cellworks myCare-040 Study Demonstrates Predictive Power of Computational Modeling to Guide Chemo-Immunotherapy Decisions in Advanced NSCLC

-Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Best-in-Class PTRS, announced results from the landmark myCare-040 clinical ...

September 09, 2025 | Tuesday | News
Corner Therapeutics Unveils Breakthrough Hyperactivator Technology Showing Potential for a Universal Influenza Vaccine and Cancer Immunotherapy

Corner Therapeutics, an in vivo T cell modulation and immunotherapy company pioneering novel approaches to cancer and infection, published research in mB...

September 09, 2025 | Tuesday | Reports
Northstrive Biosciences and Yuva Biosciences Complete Phase II of AI-Driven Drug Discovery Program

Northstrive Biosciences and Yuva Biosciences previously announced the AI Development Program, a collaboration leveraging MitoNova™, YuvaBio&rsquo...

September 08, 2025 | Monday | News
Daiichi Sankyo and Merck Report Positive Phase 2 Results for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer

Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the Phase 2...

September 08, 2025 | Monday | News
Science 37 and Catalent Partner to Transform Clinical Trial Access with Direct-to-Patient IMP Delivery

Science 37, the leader in expanding patient access to clinical trials, and Catalent®, a global leader in enabling pharma, biotech, and consumer healt...

September 05, 2025 | Friday | News
New Jersey: A Leading Life Sciences Manufacturing Hub

New Jersey at a Glance – Often dubbed the “Medicine Chest of the World,” New Jersey has a rich legacy and a dynamic present as a global h...

September 03, 2025 | Wednesday | Reports
MEDIPAL and JCR Partner on Global Development of JR-479 for Ultra-Rare GM2 Gangliosidosis

MEDIPAL HOLDINGS CORPORATION (TSE 7459, MEDIPAL) and JCR Pharmaceuticals Co., Ltd. (TSE 4552, JCR) announced that the two companies have signed an exclus...

September 03, 2025 | Wednesday | News
Boehringer Ingelheim’s HERNEXEOS® (zongertinib) Receives NMPA Approval for HER2-Mutant Advanced NSCLC in China

Boehringer Ingelheim  announced that China’s National Medical Products Administration (NMPA) has approved HERNEXEOS® (zongertinib tablets)...

September 02, 2025 | Tuesday | News
Novartis Leqvio Achieves Landmark Results in V-DIFFERENCE Phase IV Study

V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LD...

September 02, 2025 | Tuesday | News
Roche and Alnylam Target Uncontrolled Hypertension with ZENITH Phase III Trial

Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3 In the Phase II KA...

September 02, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close